Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Corvus Pharmaceuticals, Inc. (CRVS)

Corvus Net Loss Widens to $20.3 Million in Q3 2026; Cash Totals $202.9 Million

Negative Impact 3 of 5 earnings Written later

Corvus Pharmaceuticals reported a third-quarter 2026 net loss of $20.3 million, up from $10.2 million a year earlier, as research and development expenses rose to $17.8 million from $8.5 million. The company had $202.9 million in cash, cash equivalents and marketable securities at September 30, 2026, which it says will fund operations into the second quarter of 2028.

Key points

  • Q3 2026 net loss was $20.3 million, or $0.22 per share, versus $10.2 million, or $0.12 per share, in Q3 2025.
  • Research and development expenses were $17.8 million for the quarter, up $9.3 million, mainly from higher clinical trial costs for soquelitinib.
  • Cash, cash equivalents and marketable securities were $202.9 million at September 30, 2026, including about $189.4 million in net proceeds from a financing completed January 23, 2026.
  • The company said its cash is expected to fund operations into the second quarter of 2028.

The filing

CompanyCorvus Pharmaceuticals, Inc. (CRVS)
Form8-K, current report
Filed with the SECNov 5, 2026, 4:02 PM ET
Accession number0001171843-26-007175

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 05, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.